Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences reported Q3 2026 revenue of $13.2 million (up from $7.6 million a year ago) with a net loss of $61.9 million, or $(0.30) per share. The company is planning a registrational trial of WVE-006 for AATD with FDA-aligned interim analysis for potential accelerated approval, and dosing is underway in the Phase 2a INLIGHT obesity trial of WVE-007, with a combination trial with weekly tirzepatide and a post-incretin maintenance trial also advancing. GSK selected a GalNAc-siRNA development candidate using Wave's SpiNA design, earning Wave a $12 million milestone payable in 4Q 2026, with up to $330-$375 million in milestones per program plus royalties still available.
Key figures
- Revenue
- 13158000
- Revenue Yoy
- 73%
- Net loss
- 61912000
- Ga expense
- 25362000
- Rd expense
- 53843000
- Cash runway
- into 3Q 2028
- Gsk milestone
- 12000000
- Net loss prior year
- 53852000
- Cash and marketable securities
- 431000000
- Gsk milestone potential per program
- $330 - $375 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.